RxDoctor Payments Data

Jose Perez, MD

Nephrology · Houston, TXNPI 1831353440

Payments from drug & device makers

$24,607in general payments, 2019–2025

Across 133 payments — averaging $185.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$13K
  • Amgen$3K
  • Apellis Pharmaceuticals, Inc.$2K
  • AstraZeneca$2K
  • Calliditas Therapeutics US Inc.$2K
  • Aurinia Pharma U.S., Inc.$600
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$5,03620%
  • Speaking & faculty fees$13,02853%
  • Travel & lodging$1,1815%
  • Food & beverage$5,32122%
  • Education$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,607 in reported general payments places this provider in the 85th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$119,056
Medicare patients
99
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide32$58,396
Sevelamer Carbonate158$56,817
AuryxiaFerric Citrate21$42,564
LokelmaSodium Zirconium Cyclosilicate42$35,787
FarxigaDapagliflozin Propanediol27$25,715
JardianceEmpagliflozin16$23,555
VeltassaPatiromer Calcium Sorbitex15$14,810
EliquisApixaban14$12,150
Nifedipine ErNifedipine165$4,821
Midodrine Hcl19$1,429
Tamsulosin Hcl71$1,247
Bumetanide29$961
Furosemide110$665
Carvedilol113$593
Labetalol Hcl12$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$2,057$61,50269 claims
Fresenius USA Marketing, Inc.Velphoro$294$58,39632 claims
Akebia Therapeutics IncAuryxia$12,915$42,56421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →